Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 8—August 2021
CME ACTIVITY - Research

Fungemia and Other Fungal Infections Associated with Use of Saccharomyces boulardii Probiotic Supplements

Juha RannikkoComments to Author , Ville Holmberg, Matti Karppelin, Pertti Arvola, Reetta Huttunen, Eero Mattila, Niina Kerttula, Teija Puhto, Ülle Tamm, Irma Koivula, Risto Vuento, Jaana Syrjänen, and Ulla Hohenthal
Author affiliations: Tampere University, Tampere, Finland (J. Rannikko); Tampere University Hospital, Tampere (J. Rannikko, M. Karppelin, P. Arvola, R. Huttunen, J. Syrjänen); University of Helsinki, Helsinki, Finland (V. Holmberg); Helsinki University Hospital, Helsinki (V. Holmberg, E. Mattila); Oulu University Hospital, Oulu, Finland (N. Kerttula, T. Puhto); Kuopio University Hospital; Kuopio Finland (Ü. Tamm, I. Koivula); Fimlab Laboratories, Tampere (R. Vuento); Turku University Hospital, Turku, Finland (U. Hohenthal)

Main Article

Table 3

Saccharomyces clinical culture findings (excluding fungemias), Finland, January 1, 2009‒December 31, 2018*

Characteristic All
 University hospital district
Total Helsinki Tampere Turku Oulu Kuopio
Catchment area in 2017 3,310,000 1,650,000 530,000 480,000 400,000 250,000
Inpatient days in 2017
 1,814,183
 784,252
 307,484
294,834
 191,612
 236,001
Patients who had clinical findings 1,344 649 30 215 285 165
Abdominal region 205 67 21 8 76 33
Oral or respiratory tract 676 387 6 71 137 75
Fecal 191 53 1 130 4 3
Other or unspecified
 272
 142
 2
6
 68
 54
Patients who had medical record of Saccharomyces cerevisiae var. boulardii probiotic per clinical finding† 24/125 (19) 3/25 (12) 6/25 (24) 4/25 (16) 4/25 (16) 7/25 (28)
Abdominal region 15 2 4 1 4 4
Oral or respiratory tract 4 0 1 3 0 0
Other or unspecified
 5
 1
 1
0
 0
 3
Patients who had medical record of S. cerevisiae var. boulardii probiotic in control group 3/123 (2) 0/25 (0) 1/25 (4) 0/23 (0) 0/25 (0) 2/25 (8)
No. patients who had change of antimicrobial drugs because of finding of Saccharomyces sp.‡ 44/125 (35) 11/25 (44) 3/25 (12) 8/25 (32) 13/25 (52) 9/25 (36)

*Values are no. or no. positive/no. tested (%). †Fecal samples excluded. The most recent 25 case-patients per hospital district checked. Medical records not available for 6 case-patients. Kuopio last 3 mo of probiotic use, others last 7 d. ‡Medical records not available for 2 case-patients.

Main Article

Page created: May 10, 2021
Page updated: July 14, 2021
Page reviewed: July 14, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external